.png)
Nurami Medical
Electrospun-nanofiber dural-repair patch for neurosurgery (ArtiFascia)
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Nurami Medical is positioned as an early-commercial medtech company focused on electrospun nanofiber implants for dura repair and broader soft-tissue regeneration, with a clear push from product validation into commercialization and pipeline expansion.[2][8][18] Its trajectory is strongest on technical differentiation and regulatory-backed market entry, while public operating signals suggest a small but active organization still scaling execution capacity.[3][6][18]
Efficiency Ratio
The company appears relatively efficient at converting a modest team and limited public footprint into high-value technical milestones, including FDA clearance and material grant/funding wins.[3][8][11][18]
Evidence Signals
Website and company profiles identify ArtiFascia as an FDA-cleared 510(k) dural repair product and Nurami’s first commercial product.
Nurami Medical announced completion of a capital funding round expected to result in $30 million in financing for commercialization of ArtiFascia and clinical development of ArtiFix.
The company received a €2.5 million EIC grant to accelerate soft tissue repair development.
Nurami previously raised $6 million in a financing round led by Almeda Ventures to support clinical trial completion and regulatory approval processes.
The company’s core platform is based on proprietary electrospun nanofiber and biomaterial technology for soft tissue surgical repair.
LinkedIn lists the company as privately held, founded in 2014, with 11-50 employees and 4,229 followers.
PitchBook lists Nurami at 15 employees, reinforcing that it remains a small-scale organization.
- About
- Israeli regenerative-medicine / medical-device company (HQ Haifa, Israel), founded in 2014 by Dr. Amir Bahar (Weizmann/Technion) and Nora Nseir Manassa (Technion; co-CEO/CTO). Nurami builds bio-surgical implants from electrospun nanofiber scaffolds that mimic native tissue. Its first product, ArtiFascia®, is a multilayer biomimetic dural-repair graft for neurosurgery — a resorbable patch that promotes neodura regeneration while a barrier layer prevents cerebrospinal-fluid leaks and bacterial penetration; FDA 510(k)-cleared (2023) and in early US commercial sales. A second product, ArtiFix® (a sutureless dural adhesive patch for spine/neurosurgery), is in development (EIC-backed, pre-FiH). ~$44M raised. Note: this is a civilian neurosurgical soft-tissue-repair implant; its combat-casualty relevance is thin and downstream (dural repair after penetrating head/spine trauma) — the weakest defense fit in the C12-03 set.
- Tags
- #durarepair #neurosurgery #electrospun #nanofiber #softtissue #regenerative #implant #fda #csfleak